Atypical Hemolytic Uremic Syndrome (aHUS) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target 
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company Profiles
6.1. Alexion Pharmaceuticals
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Alnylam Pharmaceuticals, Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Akari Therapeutics
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. ChemoCentryx, Inc.
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Swedish Orphan Biovitrum AB
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Omeros Corporation
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Amgen Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. Achillion Pharmaceuticals, Inc.
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Greenovation Biotech GmbH
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Ra Pharmaceuticals, Inc.
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services